» Articles » PMID: 27648001

Effects for Sequential Treatment of SiAkt and Paclitaxel on Gastric Cancer Cell Lines

Overview
Journal Int J Med Sci
Specialty General Medicine
Date 2016 Sep 21
PMID 27648001
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Real-time screening of cellular response on the drugs could provide valuable insights for the early detection of therapeutic efficiency and the evaluation of disease progression. Cancer cells have the ability to vary widely in response to stress in a manner to adjust the signaling pathway to promote the survival or having a resistance to stimulation. Cell-based label-free technologies using electronic impedance sensor have strategies for constructing the signature profiles of each cells. To achieve exquisite sensitivity to substantially change of live-cell response have an important role that predict the potential of therapeutic effects. In this study, we use an impedance-based real-time cell analysis system to investigate dynamic phenotypes of cells described as a cellular index value. We show that gastric cancer cells generated characteristic kinetic patterns that corresponded to the treatment order of therapeutics. The kinetic feature of the cells offers insightful information that cannot be acquired from a conventional single end-point assay. Furthermore, we employ a 'sequential treatment strategy' to increase cytotoxic effects with minimizing the use of chemotherapeutics. Specifically, treatment of paclitaxel (PTX) after down-regulating Akt gene expression using RNAi reduces the cell proliferation and increases apoptosis. We propose that the sequential treatment may exhibit more effective approach rather than traditional combination therapy. Moreover, the dynamic monitoring of cell-drug interaction enables us to obtain a better understanding of the temporal effects in vitro.

Citing Articles

Pancreatic cancer cells hijack tumor suppressive microRNA-26a to promote radioresistance and potentiate tumor repopulation.

Jiang M, Lin C, Liu F, Mei Z, Gu D, Tian L Heliyon. 2024; 10(10):e31346.

PMID: 38807872 PMC: 11130661. DOI: 10.1016/j.heliyon.2024.e31346.


Bioactive Ent-Kaurane Diterpenes Oridonin and Irudonin Prevent Cancer Cells Migration by Interacting with the Actin Cytoskeleton Controller Ezrin.

Pagliara V, Donadio G, De Tommasi N, Amodio G, Remondelli P, Moltedo O Int J Mol Sci. 2020; 21(19).

PMID: 33003361 PMC: 7582544. DOI: 10.3390/ijms21197186.


Evaluation of IC levels immediately after treatment with anticancer reagents using a real-time cell monitoring device.

Hazekawa M, Nishinakagawa T, Kawakubo-Yasukochi T, Nakashima M Exp Ther Med. 2019; 18(4):3197-3205.

PMID: 31555392 PMC: 6755379. DOI: 10.3892/etm.2019.7876.


Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers.

Kamble S, Sen A, Dhake R, Joshi A, Midha D, Bapat S J Clin Med. 2019; 8(3).

PMID: 30857227 PMC: 6463261. DOI: 10.3390/jcm8030330.

References
1.
Rebucci M, Michiels C . Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 2013; 85(9):1219-26. DOI: 10.1016/j.bcp.2013.02.017. View

2.
Dowling C, Herranz Ors C, Kiely P . Using real-time impedance-based assays to monitor the effects of fibroblast-derived media on the adhesion, proliferation, migration and invasion of colon cancer cells. Biosci Rep. 2014; 34(4). PMC: 4114067. DOI: 10.1042/BSR20140031. View

3.
MacKeigan J, Taxman D, Hunter D, Earp 3rd H, Graves L, Ting J . Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res. 2002; 8(7):2091-9. View

4.
Atienzar F, Tilmant K, Gerets H, Toussaint G, Speeckaert S, Hanon E . The use of real-time cell analyzer technology in drug discovery: defining optimal cell culture conditions and assay reproducibility with different adherent cellular models. J Biomol Screen. 2011; 16(6):575-87. DOI: 10.1177/1087057111402825. View

5.
Cheng J, Sakamoto K . The emerging role of RNA interference in the design of novel therapeutics in oncology. Cell Cycle. 2004; 3(11):1398-401. DOI: 10.4161/cc.3.11.1240. View